Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease

被引:17
作者
Kiaii, S
Choudhury, A
Mozaffari, F
Kimby, E
Österborg, A
Mellstedt, M [1 ]
机构
[1] Karolinska Univ Hosp, Dept Oncol, SE-17176 Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Haematol, SE-17176 Stockholm, Sweden
[3] Karolinska Univ Hosp, Canc Ctr, SE-17176 Stockholm, Sweden
关键词
T-cell; B-CLL; signaling; indolent; progressive;
D O I
10.1385/MO:22:3:291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
T-cell dysfunction in B-CLL patients might be attributed to altered expression of components of the TCR/CD3 complex and associated intracellular tyrosine kinases. Four-color flow cytometry was applied to the expression of these molecules as well as the T-cell regulatory cytokines (IFN-gamma and IL-4) in B-CLL patients with indolent and progressive disease. Intracellular levels [mean fluorescent intensity (MFI)] of IFN-7 gamma and IL-4 in both CD4 and CD8 T cells of both patient groups were significantly higher than in healthy donors. Absolute number of IL-4 producing CD4 T cells in patients with indolent was significantly higher than in healthy donors. The expression level (MFI) of the CD3-zeta chain was higher in patients than in normal donors as well as ZAP-70 in patients with indolent disease as compared to healthy donors and progressive patients. No significant difference was noted in the expression of p56(lck), p59(fyn), and PI3-kinase between healthy donors and patients or between the patient subgroups. The results indicate multiple T-cell abnormalities especially in indolent-stage B-CLL suggesting a state of chronic and aberrant activation. This information might be of significance when studying the immunobiology of B-CLL as well as developing new therapeutic approaches.
引用
收藏
页码:291 / 302
页数:12
相关论文
共 44 条
[1]   T cell activation and the cytoskeleton [J].
Acuto, O ;
Cantrell, D .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :165-+
[2]  
Bartik MM, 1998, SEMIN ONCOL, V25, P27
[3]  
BOYUM A, 1977, LYMPHOLOGY, V10, P71
[4]   T-CELLS AND CD45R EXPRESSION IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
BRIGGS, PG ;
KRAFT, N ;
ATKINS, RC .
LEUKEMIA RESEARCH, 1990, 14 (02) :155-159
[5]   INTERFERON GAMMA INHIBITS APOPTOTIC CELL-DEATH IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
BUSCHLE, M ;
CAMPANA, D ;
CARDING, SR ;
RICHARD, C ;
HOFFBRAND, AV ;
BRENNER, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (01) :213-218
[6]   Role of the microenvironment in chronic lymphocytic leukaemia [J].
Caligaris-Cappio, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (03) :380-388
[7]   FUNCTIONAL ABNORMALITIES ASSOCIATED WITH LYMPHOCYTES-T FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
CALLERY, RT ;
STRELKAUSKAS, AJ ;
YANOVICH, S ;
MARKS, S ;
ROSENTHAL, D ;
SCHLOSSMAN, SF .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1980, 17 (03) :451-458
[8]  
CATOVSKY D, 1974, LANCET, V2, P751
[9]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[10]   Rapid recovery from T lymphopenia by CD28 superagonist therapy [J].
Elflein, K ;
Rodriguez-Palmero, M ;
Kerkau, T ;
Hünig, T .
BLOOD, 2003, 102 (05) :1764-1770